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Abstract 
Hospitalisation for acute heart failure remains a major public health problem with high 
prevalence, morbidity, mortality and cost. Prior attempts to develop new therapies for this 
condition have not been successful. Nitroxyl (HNO) plays a unique role in cardiovascular 
physiology by direct post-translational modification of thiol residues on target proteins, 
specifically SERCA2a, phospholamban, the ryanodine receptor and myofilament proteins in 
cardiomyocytes. In animal models, these biological effects lead to vasodilation, increased 
inotropy and lusitropy, but without tachyphylaxis, pro-arrhythmia or evidence of increased 
myocardial oxygen demand. BMS-986231 is an HNO donor being developed as a therapy for 
heart failure, and initial studies in patients with heart failure support the potential clinical value 
of these physiological effects. In this manuscript, we describe the ongoing phase II development 
programme for BMS-986231, which consists of three related randomised placebo-controlled 
clinical trials, StandUP-AHF, StandUP-Imaging and StandUP-Kidney, which are designed to 
provide evidence of tolerability and efficacy as well as confirm the anticipated physiological 
effects in patients with heart failure with reduced ejection fraction. These studies will set the 
stage for the further study of BMS-986231 in future phase III clinical trials. 
 
Short title: HNO donor BMS-986231 in acute HF (StandUP)  
 
Keywords (max. 6): clinical trial design; heart failure; inotropy; nitroxyl; HNO donor; BMS-
986231 
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ClinicalTrials.gov identifiers: NCT03016325 (StandUP-AHF), NCT03357731 (StandUP-Imaging), 
NCT03730961 (StandUP-Kidney)  
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Introduction 
Hospitalisation for worsening heart failure (HF), often termed acute heart failure (AHF), remains 
a major public health problem with high prevalence, morbidity, mortality and cost. To date, 
attempts to develop effective new therapies for this condition have been unsuccessful. The 
reasons for the failures of prior AHF drug development programmes have been the subject of 
intense debate.1 Proposed explanations include issues around patient selection, trial conduct, 
appropriate pathophysiological targets, ideal endpoints, possibility of affecting long-term 
outcomes with short-term treatments, and whether AHF is even a distinct disease entity at all. 
Even the term “acute heart failure” is imprecise, because many patients are admitted with 
increasing fluid retention developing over days or weeks leading to peripheral oedema, 
orthopnoea and increasing exertional dyspnoea rather than breathlessness at rest.2 Despite 
these challenges, it is clear that improving the short- and long-term outcomes for these 
patients remains an unmet medical need. Accordingly, we report the rationale for a novel 
therapeutic approach to patients hospitalised with HF using an intravenous nitroxyl (HNO) 
donor, and summarise the design of the ongoing phase II development programme for this 
compound.  
 
Standard of care and goals of therapy for acute heart failure 
Because the vast majority of patients hospitalised with AHF present with signs and symptoms of 
congestion, the current standard of care consists primarily of addressing congestion with loop 
diuretics.3 In selected patients, additional therapies may be targeted at reducing 
preload/afterload with vasodilators (generally in patients with elevated blood pressure) or 
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enhancing contractility with inotropic agents (in patients with low cardiac output and/or 
impaired end organ perfusion).4 Remarkably, none of these three AHF treatment classes have a 
strong evidence base to support their use.4, 5 Diuretics are a mainstay of treatment and provide 
symptomatic benefit in most patients, but have not been rigorously tested in placebo-
controlled trials in patients hospitalised with HF. Placebo controlled trials of vasodilators and 
inotropes in combination with standard therapy in AHF have generally shown very modest (or 
absent) clinical benefits, and have sometimes been harmful.6-8 Broadly speaking, the treatment 
goals for a patient hospitalised with AHF are straightforward: (1) rapid and complete relief of 
symptoms; (2) prevention of in-hospital mortality or clinical deterioration; (3) safely minimising 
length of hospital stay (LOS) and resource utilisation (e.g. ICU stay); (4) reducing the likelihood 
of readmission after discharge; and (5) reducing long-term mortality. As management becomes 
increasingly complex, efforts to streamline and simplify care are also important. Any novel 
therapy directed at this problem needs to have a clinically relevant impact on at least one or 
more of the above goals to be considered an important advance.  
 
Rationale for HNO therapy in heart failure 
Nitroxyl (HNO) gas is a chemical sibling of nitric oxide (NO); although NO and HNO appear to be 
closely related chemically, HNO exists only in the protonated form in physiological settings and 
does not readily interconvert with NO. Importantly, the physiological effects and biological 
mechanisms of HNO and NO action are highly distinct.9 The biological effects of HNO are 
reversible and mediated by direct post-translational modification of thiol residues in target 
proteins, specifically SERCA2a, phospholamban, the ryanodine receptor and myofilament 
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proteins in cardiomyocytes.10-14 In vitro, HNO increases the efficiency of calcium cycling, 
improves myofilament sensitivity to calcium and enhances cardiac contractility and lusitropy via 
the above proteins.15 HNO also mediates peripheral vasodilation in a manner dependent on 
soluble guanylate cyclase in the endothelium. Importantly, unlike the activity of NO, 
tachyphylaxis does not appear to impact the effects of HNO in the peripheral vasculature.16 The 
effects of HNO do not appear to be mediated by adrenergic receptors, which may be important 
given the nearly ubiquitous use of use of beta-blockers in HF.17 A schematic of the putative 
mechanisms of action of HNO on the heart is shown in Figure 1.  
HNO donors release HNO via chemical breakdown upon exposure to the physiological 
aqueous environment. In large animal models of HF, HNO donors directly enhance both 
contractility and relaxation and reduce both preload and afterload.18, 19 Despite reliable 
augmentation of inotropy and lusitropy in these models, HNO donors do not increase heart rate 
or myocardial oxygen consumption, nor do they result in QT prolongation.18, 19 This 
combination of physiological effects makes HNO donors potentially attractive therapeutic 
candidates in HF. 
BMS-986231 is an HNO donor in development for HF. In early clinical studies, BMS-
986231 exhibited a short plasma elimination half-life of approximately 1 hour, with a mean 
time to steady state of approximately 3 hours. Less than 1% of prodrug is eliminated in urine, 
the majority of dose was excreted in urine as metabolites that are not expected to exert 
significant physiological effects. It has low potential for drug-drug interactions at anticipated 
plasma concentrations. In euvolemic healthy volunteers, BMS-986231 reduced blood pressure 
at escalating doses but did not cause symptomatic hypotension.20 BMS-986231 was generally 
 8 
well tolerated, with the emergence of headache as a likely drug-related adverse event at higher 
doses. In a study of patients with HF and hypervolaemia, BMS-986231 reduced blood pressure 
to a much lesser extent and headaches were infrequent during the infusion.21 In this early proof 
of concept study, a 6-hour infusion of BMS-986231 produced rapid and sustained decreases in 
intracardiac filling pressures and suggested improvements in non-invasively measured cardiac 
index (by thermodilution but not by Fick) in 46 patients with advanced HF with reduced ejection 
fraction (HFrEF). There was also no increase in tachycardia, arrhythmia or symptomatic 
hypotension with BMS-986231 compared with placebo.21 However, BMS-986231 was 
administered for a short duration and vasoactive medications, including intravenous (IV) or oral 
diuretics, were prohibited for ≥4 hours prior to baseline haemodynamic assessment until 
completion of the 6-hour infusion.  
 In summary, data from large animal models and initial human studies suggest that BMS-
986231 has multiple and potentially beneficial haemodynamic effects in patients with HF. These 
include peripheral vasodilation as well as improvements in contractility (inotropy) and 
ventricular relaxation (lusitropy), all without evidence of the adverse effects seen with existing 
inotropes, such as pro-arrhythmia or myocardial ischemia.  
 
Challenges in phase II studies in acute heart failure 
Broadly speaking, phase II studies in cardiovascular disease are intended to show target 
engagement, assess for signals of efficacy and safety in the target patient population, allow for 
selection of appropriate dose or doses for future study and refine estimates of treatment effect 
for the planning of larger more definitive trials. In AHF, all of these goals have been persistently 
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challenging. There is no accepted and validated surrogate endpoint that might be used in phase 
II studies in AHF to predict clinically important treatment effects in larger trials.22 The absence 
of validated surrogate endpoints for efficacy presents challenges in terms of making a decision 
to proceed to phase III trials as well as for decisions about dose selection. Although adaptive 
designs are increasingly used in early phase studies in other areas of medicine, the lack of a 
reliable surrogate endpoint has limited the ability to utilise this approach in HF.23 In this 
context, the goals of the phase II development programme for the HNO donor BMS-986231 are 
as follows: 
1) Establish tolerability of one or more doses of BMS-986231 in patients hospitalised 
with heart failure and reduced ejection fraction (EF; ≤40%), specifically with regard to 
the incidence of symptomatic hypotension. 
2) Identify signals of efficacy and/or safety in these patients, specifically effects on 
symptoms, evidence of congestion, natriuretic peptides, length of stay, the incidence of 
worsening HF, rehospitalisation for HF, and mortality. 
3) Evaluate whether BMS-986231 improves systolic and diastolic function in patients 
with stable HF through an echocardiographic cross-over study. 
4) Evaluate whether BMS-986231 alters the excretion of water and salt or enhances the 
effects of diuretic agents in patients with stable HF. 
These goals are being pursued through three separate, randomised, double-blind controlled 
trials, each described briefly below.  
 
The StandUP-AHF study 
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StandUP-AHF (STudy Assessing Nitroxyl Donor Upon Presentation with Acute Heart Failure) is a 
multicentre, randomised, double-blind, placebo-controlled, ascending dose trial of continuous 
48-hour IV infusions of BMS-986231 vs. placebo in hospitalised patients with AHF and impaired 
ejection fraction (≤40%). The primary objective of the study is to evaluate the effects of various 
doses of BMS-986231 compared with placebo on clinically relevant hypotension (defined as 
systolic blood pressure [SBP] <90 mmHg or symptoms of hypotension). The study consists of 
two parts, each with a unique cohort of patients.  
In Part I (Cohort 1), approximately 100 patients are randomised in a 1:1 ratio to 
escalating doses of BMS-986231 (3 g/kg/min for 4 hours, then 6 g/kg/min for another 4 
hours, followed by 12 g/kg/min for the remaining 40 hours) or escalating doses of placebo. In 
Part II (Cohort 2) of the study, the two highest-tolerated doses of BMS-986231 in Cohort 1 
(BMS-986231 6 g/kg/min and 12 g/kg/min) are administered. Approximately 210 patients 
are randomised in a 1:1:1 ratio to one of the two active doses of BMS-986231 or placebo. A 
schematic for the overall design of the StandUP-AHF study is shown in Figure 2.  
 
Study population 
The key inclusion and exclusion criteria for StandUP-AHF are provided in Table 1. Briefly, 
patients must be hospitalised for HF with signs and symptoms of congestion requiring 
treatment with IV loop diuretics. Patients must have a history of chronic HF and documented 
ejection fraction ≤40% within the prior 18 months. Patients with SBP <105 mmHg or >160 
mmHg are excluded. Patients receiving IV vasodilators or IV inotropic agents are also excluded, 
except for those receiving IV or transdermal nitrate therapy with SBP >120 mmHg and receiving 
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a stable dose of nitrates with a dose <100 µg/min. For Cohort 1, patients had to be randomised 
within 18 hours of their initial dose of IV loop diuretics. This time window has been expanded to 
48 hours for Cohort 2 to better capture the spectrum of patients that might be targeted in 
potential phase III trials. 
 
Treatment and strategies to mitigate hypotension 
In StandUP-AHF, patients are treated with IV BMS-986231 or matching placebo in a double-
blind fashion for 48 hours. In Cohort 1, doses were escalated every 4 hours for the first 8 hours. 
In Cohort 2, patients are treated with their assigned dose throughout the 48-hour treatment 
period. Background therapy for HF is standard of care based on the patient’s clinical status.  
 Avoiding hypotension is an important safety goal during the treatment of AHF, 
particularly when treating with IV vasodilators. In the StandUP-AHF study, a protocol for 
adjusting the BMS-986231 dose based on SBP and potential symptoms of hypotension is used 
(Figure 3). Briefly, if a patient experiences SBP 94-85 mmHg without symptoms of hypotension, 
the blood pressure measurement must be repeated within 15 minutes. If SBP remains within 
this range, the dose is reduced by 50%. If SBP falls below <85 mmHg (and remains <85 mmHg 
following a repeated measurement within 15 minutes), or if the patient experiences symptoms 
of hypotension (regardless of blood pressure), the study drug must be interrupted for at least 1 
hour and then resumed at 50% of the prior dose, provided that SBP is now ≥105 mmHg and 
symptoms of hypotension have resolved. After dose reductions, the dose is not increased 
further. BMS-986231 must be permanently discontinued after it has been down-titrated once 
and criteria for dose reduction or interruption have been met again. 
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Endpoints and assessments 
The primary endpoint for StandUP-AHF is the incidence of clinically relevant hypotension, 
defined as SBP <90 mmHg (confirmed by repeat measurement) or symptoms of hypotension up 
to 6 hours after the end of study infusion. Secondary endpoints are change in N-terminal pro-B-
type natriuretic peptide from baseline at various time points and change in patient-reported 
resting dyspnoea using the area under the curve of an 11-point numerical rating scale 
(dyspnoea assessed on a scale of 0-10) from baseline to 72 hours. Other endpoints of interest 
are the incidence of worsening HF (defined as worsening signs or symptoms of HF and the need 
to escalate therapy) through Day 5 (or discharge), changes in renal function, changes in signs 
and symptoms of congestion, length of stay, patient global assessment, physical activity tracked 
using wearable accelerometry, and post-discharge death or rehospitalisation through Day 32. 
Patients will be followed through Day 182 for mortality as a safety endpoint. Adverse events 
will be captured through Day 32.  
 
Interim analysis and statistical considerations 
For Part I (Cohort 1), approximately 50 patients per group are randomised to placebo or an 
incremental dose of BMS-986231 (3 to 6 to 12 μg/kg/min). Under a sample decision rule (e.g. 
observed doubling with a difference of more than 4%) and assuming clinically relevant 
hypotension incidences of 5% or 10% in the placebo group, the posterior probabilities of 
detecting a 4- or 3-fold increase in these respective incidences are 86% and 80%, respectively. If 
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there is no increase in clinically relevant hypotension, the posterior probabilities of falsely 
detecting an increase are 11-12%.  
Upon completion of Part I, an interim analysis was conducted to select the BMS-986231 
doses for use in Part II. This was conducted in an unblinded fashion by the study executive 
committee and the study sponsor, with input from the data safety monitoring committee. As 
noted previously, the doses selected for Part II (based on the overall totality of the available 
safety and efficacy data) were the two highest doses administered in Part I; specifically, BMS-
986231 6 g/kg/min and 12 g/kg/min.  
For Part II (Cohort 2), approximately 70 patients per group are randomised to placebo or 
one of the two BMS-986231 doses. Under a sample decision rule (e.g. observed 1.8-fold 
increase with a difference of more than 3%) and assuming clinically relevant hypotension 
incidences of 5% or 10% in the placebo group, the posterior probabilities of detecting a 3- or 
2.5-fold respective increase in hypotension incidence are 82% and 80%, respectively. If there is 
no increase in clinically relevant hypotension, then the posterior probabilities of falsely 
detecting an increase are 13-15%. These probabilities do not reflect multiple comparisons. 
 
The StandUP-Imaging study 
Studies of drugs whose primary physiological effect is acute vasodilation have generally not 
demonstrated substantial clinical benefit in AHF. Given that the mechanism of action for HNO 
donors suggests they would have potentially clinically important effects on inotropy and 
lusitropy, the StandUP-Imaging study is designed to evaluate the effects of BMS-986231 
compared with those of nitrates or placebo in patients with HF. Detecting such physiological 
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effects in the context of AHF is challenging, as background therapy changes over time and 
loading conditions change dramatically with decongestive therapies. Therefore, the StandUP-
Imaging study uses a crossover design to evaluate the physiological effects of BMS-986231 in 
patients with chronic stable HF with ejection fraction <40% and who are in sinus rhythm (see 
Figure 4 for study design and Supplementary Table S1 for inclusion and exclusion criteria). 
StandUP-Imaging is a multicentre, randomised, crossover, placebo and active-controlled 
double-blind study of continuous 5-hour IV infusions of BMS-986231 designed to evaluate the 
drug’s effect on systolic and diastolic parameters, as measured by echocardiography using a 
central core laboratory. Each patient receives the three interventions (BMS-986231, 
nitroglycerin [NTG] and placebo) across three treatment periods, with one intervention 
occurring during each period. Each of these periods includes a 5-hour infusion of BMS-986231, 
NTG or placebo, followed by a washout period. Forty-two study participants are being 
randomised to receive BMS-986231, NTG and placebo in one of the six possible sequences 
(Figure 4). In the event of a decrease in SBP, an algorithm is used to down-titrate, interrupt or 
discontinue the study drug infusion, similar to that described for the StandUP-AHF study (Figure 
3).  
 
Assessments and endpoints 
A core lab performs all echocardiographic analyses in the StandUP-Imaging study. Prior to 
enrolment, participants undergo a screening echocardiography that is submitted to the core lab 
for review to confirm eligibility. At least two echocardiograms are performed on the first day of 
each period (prior to infusion and near the end of the infusion between Hour 4 and Hour 5).  
 15 
 The primary endpoint is stroke volume index derived from the left ventricular outflow 
tract. Comparisons between placebo and BMS-986231 are performed using a mixed model 
repeated measures analysis, controlling for treatment sequence, treatment period, specific 
treatment (i.e. BMS-986231 or placebo) and the difference in the treatment period baselines. 
Secondary comparisons of interest include that between BMS-986231 and NTG, as well as 
comparison to placebo and NTG on selected other left ventricle systolic and diastolic indices (LV 
ejection fraction, tissue Doppler, LV diastolic function, including indices that have been shown 
to be less load-dependent such as LV power index, LV global longitudinal and circumferential 
strain with speckle tracking echocardiography, LV end-systolic elastance and LV myocardial 
performance index). In addition, other parameters are part of the echo examination protocol 
and will be assessed: LV structure, dimensions, mitral inflow, LA size and function, RV size and 
function, pulmonary vascular assessment and valvular assessment.  
 
The StandUP-Kidney study 
Decongestion is a major therapeutic goal in patients with decompensated HF.24, 25 Given its 
mechanism of action, BMS-986231 might alter water- and salt-handling by direct renal actions 
or by its haemodynamic effects, and could also alter the activity of loop diuretics. However, it is 
difficult to study the effects of diuretics in patients with unstable, worsening HF, especially if 
the patient is to act as their own control in a crossover trial. Accordingly, a double-blinded, 
randomised, placebo-controlled two-way crossover study to evaluate the effects of BMS-
986231 on 4-hour urine output in patients after administration of 40 mg of IV furosemide is 
being undertaken. Enrolled patients have chronic HF with an ejection fraction <45%, are on 
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stable, guideline-directed medical therapy for HF, including at least 40 mg oral furosemide (or 
equivalent) daily, and have elevated natriuretic peptides. The StandUP-Kidney study consists of 
two 1-day treatment periods (BMS-986231 or placebo) separated by a washout period. 
Approximately 20 patients will be studied (See Supplementary Table S2 for key inclusion and 
exclusion criteria). BMS-986231 or placebo is administered in a blinded manner for 8 hours as 
continuous IV infusion. At Hour 4 after infusion start, a 40-mg IV bolus of furosemide is 
administered to both treatment groups through a separate IV line, given slowly over 1-2 
minutes. If blood pressure drops or symptomatic hypotension occurs, the infusion may be 
slowed or stopped, similar to that described for the StandUP-AHF study (Figure 3). As 
mentioned previously, the primary objective is to evaluate the effects of BMS-986231 on 4-
hour urine output against a background of administration of 40 mg of IV furosemide. Secondary 
endpoints include the effect of BMS-986231 on fractional excretion of sodium and potassium, 
as well as urinary and plasma concentrations of furosemide.  
 
Discussion 
Given the lack of success in developing new therapies for patients hospitalised with AHF, the 
ideal design for phase II development programmes remains uncertain. Suggested reasons for 
the failure of prior programmes include a lack of understanding of the drug’s mechanism of 
action in the target population, inappropriate patient selection or endpoints, or issues of trial 
conduct. In this paper, we have reviewed the design and rationale for the ongoing development 
of a novel HNO donor for patients hospitalised with AHF. BMS-986231 has displayed a variety of 
potentially favourable haemodynamic effects in patients with HF, including vasodilation, 
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increased contractility (inotropy) and improved ventricular relaxation (lusitropy), without 
evidence of adverse effects such as pro-arrhythmia or increases in myocardial oxygen demand.  
 The BMS-986231 development programme has several important objectives. First, it will 
assess how well various doses of BMS-986231 are tolerated in the target population of patients 
hospitalised with AHF. Although vasodilator drugs can be targeted primarily at HF patients with 
elevated blood pressure at presentation, such patients are known to have a relatively good 
prognosis and are therefore in less need of novel therapies.26 StandUP-AHF is enrolling patients 
across a spectrum of blood pressure values (from SBP 105-160 mmHg) that represent a broad 
cohort of patients hospitalised with AHF (approximately 70% of patients, based on data from 
the OPTIMIZE registry).26 The primary endpoint of StandUP-AHF is tolerability with regard to 
hypotension. Additionally, this study is enrolling patients across a relatively wide time window 
from hospitalisation, with Cohort 1 enrolled within 18 hours and Cohort 2 enrolled within 48 
hours (with time zero being defined as the initial dose of IV loop diuretic). This recognises that a 
paradigm of emphasising rapid “time to treatment” has generally not been successful in prior 
studies, and that it may be patients who do not respond well to initial therapy with diuretics 
who have the largest unmet medical need. Such patients are more likely to have a higher 
burden of comorbidities, greater diuretic resistance, more complicated in-hospital course, 
longer length of hospital stay, and greater post-discharge morbidity and mortality.  
 An important criticism of prior programmes in AHF has been that the mechanism of 
action and physiological effects of the drug candidate were incompletely understood. In that 
light, a second major goal of the development programme is to understand the effects of BMS-
986231 on relevant physiology in patients with HF. In particular, this programme will 
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investigate the effects of BMS-986231 on physiological effects beyond vasodilation alone. Using 
a crossover design, the StandUP-Imaging study is comparing the haemodynamic effects of BMS-
986231 with those of nitrates and placebo to determine whether the targeted dose range has 
demonstrable effects on inotropy and lusitropy beyond those induced by changes in loading 
conditions alone. The StandUP-Kidney study will assess whether BMS-986231 has additive 
effects on top of loop diuretics in improving decongestion in patients with HF. To minimise 
other sources of variability over time, both StandUP-Imaging and StandUP-Kidney will enrol 
patients with stable chronic HF. While this approach will limit other sources of variability, one 
potential limitation is the need to extrapolate findings from patients with stable heart failure to 
those with acute decompensation. 
In summary, the results of the three described studies should provide information on 
the safety and tolerability of BMS-986231 as well as signals of efficacy across a broad spectrum 
of the potential target population. They should also provide an understanding of relevant 
physiology with regard to haemodynamics and decongestion. The results of these studies will 
inform the continued development of BMS-986231 for patients with HF. 
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Legends 
 
Figure 1 Schematic of putative mechanism of action of HNO on the cardiovascular system.  
 
HNO exerts its physiological effects by direct post-translational modification of SH on target proteins, including 
SERCA2a, PLN, the RyR2, and myofilament proteins in cardiomyocytes. Adapted with permission from Tocchetti 
CG, et al. Antioxid Redox Signal. 2011;14:1687-1698. 
 
Ca2+, calcium; HNO, nitroxyl; LTCC, L-type calcium channel; MHC, myosin heavy chain; MLC, myosin light chain; 
PLN, phospholamban; RyR2, ryanodine receptor; SERCA, sarcoplasmic reticulum calcium2+ adenosine 
triphosphatase; SH, thiol residues; SR, sarcoplasmic reticulum. 
 
 
 
Figure 2 Schematic of (A) Part I (Cohort 1) and (B) Part II (Cohort 2) of the StandUP-AHF study.  
 
aEvery effort should be made to initiate study drug administration promptly after randomisation; bStudy drug 
infusion must start within 18 hours of presentation, defined as the first dose of diuretic for current episode, but 
not within 2 hours of an IV bolus dose of intravenous diuretics, or within 2 hours of the initiation or an increase in 
the dose of an IV diuretic administered by continuous infusion; cDischarge may occur as per standard medical 
practice. It is recommended that subjects remain in the hospital for safety monitoring for at least 24 hours after 
the completion of the 48-hour infusion of study drug; d3 μg/kg/min if 12 μg/kg/min is not tolerated in Part I;  
e6 μg/kg/min if 12 μg/kg/min is not tolerated in Part I. 
 
H, hour; D, day; R, randomisation. 
 
 
Figure 3 Protocol for dose adjustment based on systolic blood pressure in StandUP-AHF.  
 
aConfirmed by a second measurement within 15 minutes; bNo need for a confirmatory blood pressure 
measurement if symptomatic hypotension; cBut no more than 4 hours.  
 
SBP, systolic blood pressure. 
 
 
 
Figure 4 Schematic for design of the StandUP-Imaging study.  
 
aWashout period is at least 5 days and no more than 4 weeks. 
 
D, day; NTG, nitroglycerin; R, randomisation.   
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Table 1 Key inclusion and exclusion criteria for the StandUP-AHF study 
Inclusion criteria 
 Hospitalised for AHF. 
 Must have received at least 40 mg IV furosemide or equivalent for the current HF 
episode. 
 Must be randomised and treated within 18 hours of first dose of IV diuretic for Part I 
Cohort 1 (or within 48 hours of first dose for Part II Cohort 2). 
 Dyspnoea at rest or with minimal exertion after administration of at least one dose of 
IV diuretics.  
 Must not be randomised within 2 hours after an IV bolus dose of diuretics, or within 2 
hours after the initiation or a dose increase of an IV diuretic administered by 
continuous infusion. 
 History of HF and a LVEF ≤40%. 
 Evidence of congestion manifested by at least two of the following at time of 
screening:  
o Evidence of pulmonary congestion on chest X-ray. 
o Rales by chest auscultation. 
o Oedema ≥2+ on a 0-3+ scale (easily identifiable indentation, skin rebounds in 
15-30 seconds). 
o Presence of jugular venous distention.  
  
 Elevated NT-proBNP ≥1600 pg/mL (189 pmol/L) or BNP ≥400 pg/mL (116 pmol/L) as 
determined at the local laboratory within 18 hours prior to the start of study drug 
infusion for Part I Cohort 1 (or 48 hours for Part II Cohort 2). For patients with atrial 
fibrillation: NT-proBNP ≥2400 pg/mL or BNP ≥600 pg/mL. 
 Body weight ≥50 kg and ≤140 kg at screening. 
Exclusion criteria 
 SBP <105 mmHg or >160 mmHg at screening and just prior to randomisation. 
 Heart rate <50 bpm or >130 bpm at screening and just prior to randomisation. 
 Primary HF aetiology attributable to either restrictive/obstructive cardiomyopathy, 
idiopathic hypertrophic or uncorrected severe valvular disease.  
 Suspected acute lung disease (e.g. pneumonia or asthma) or severe chronic lung 
disease.  
 History of sudden cardiac death with resuscitation within the past 6 months. 
 Hospitalisation for acute coronary syndrome, coronary revascularisation or acute 
myocardial infarction during the previous 90 days.  
 History of CVA, stroke or TIA during the previous 90 days.  
 eGFR <30 mL/min/1.73 m2 (based on any standard limit and equation employed by 
the local lab, e.g. MDRD equation). 
 Haemoglobin <9 g/dL (<5.59 mmol/L).  
 Administered IV or transdermal nitrate therapy prior to randomisation, except if all 
three of the following criteria are met: 
  
o SBP at screening or just prior to randomisation is >120 mmHg.  
o The IV nitroglycerin dose is <100 µg/min (or isosorbide dinitrate <3 mg/hour).  
o The infusion rate and dose has been unchanged for >2 hours. 
 History of chronic or intermittent renal support therapy (haemodialysis, ultrafiltration 
or peritoneal dialysis). 
 Treated during the current hospitalisation with IV vasoactive drugs or has an 
anticipated need to be treated with such agents during the study drug infusion. 
 Treated with oral PDE5 inhibitor sildenafil, vardenafil or avanafil within 24 hours of 
screening or treated with tadalafil within 4 days of screening.  
 Receiving any mechanical ventilation at the time of screening. 
 Receiving non-invasive ventilation (CPAP/BiPAP) <2 hours prior to randomisation. 
AHF, acute heart failure; bpm, beats per minute; ; BiPAP, bilevel positive airway pressure; BNP, B-type natriuretic 
peptide; CPAP, continuous positive airway pressure; CVA, cerebral vascular accident; eGFR, estimated glomerular 
filtration rate; HF, heart failure; IV, intravenous; LVEF, left ventricular ejection fraction; MDRD, modification of diet 
in renal disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PDE5, phosphodiesterase type 5; SBP, 
systolic blood pressure; TIA, transient ischaemic attack.  
 
  
  
SUPPLEMENTARY MATERIAL 
 
Table S1 Key inclusion and exclusion criteria for the StandUP-Imaging study 
Inclusion criteria 
 HF with reduced ejection fraction (LVEF ≤40%). 
 On stable guideline-directed therapy for HF, including oral diuretics, ACEi, ARBs, ARNi, 
MRAs and β-blockers as tolerated, with no changes to the doses of these medications in 
the past 2 weeks. 
 Screening values of NT-proBNP ≥125 pg/mL (15 pmol/L) or BNP ≥35 pg/mL (10 pmol/L). 
 In sinus rhythm at the start of the infusion. 
Exclusion criteria 
 SBP <110 mmHg at screening or pre-randomisation. 
 Heart rate <50 bpm or >90 bpm at screening or pre-randomisation. 
 Paced rhythm (VVI, DDD or BiV pacing). 
 NYHA Class IV HF symptoms. 
 Primary HF aetiology attributable to either restrictive/obstructive cardiomyopathy, 
idiopathic hypertrophic or uncorrected severe valvular disease.  
 Prior mitral valve repair, mitral or aortic prosthesis of any type. 
 Hospitalised for acute decompensated HF in the previous month. 
 Hospitalised with acute coronary syndrome, coronary revascularisation or acute 
myocardial infarction during the previous 90 days prior to screening. 
 History of a CVA, stroke or TIA during the previous 90 days prior to screening. 
  
 Treatment with oral PDE5 inhibitor sildenafil, vardenafil or avanafil within 24 hours of 
study drug infusion or treated with tadalafil within 4 days of study drug infusion. 
 Treatment with intravenous inotropic therapy in the previous month or planned 
treatment in the next 3 months. 
 eGFR <15 mL/min/1.73 m2. 
 Low quality echocardiographic visualisation windows and image acquisition. 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNi, angiotensin receptor-
neprilysin inhibitor; bpm, beats per minute; CVA, cerebral vascular accident; eGFR, estimated glomerular filtration 
rate; HF, heart failure; LVEF, left ventricular ejection fraction, MRA, mineralocorticoid receptor antagonist; NT-
proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PDE5, phosphodiesterase 
type 5; SBP, systolic blood pressure; TIA, transient ischaemic attack.   
  
Table S2 Key inclusion and exclusion criteria for the StandUP-Kidney study 
Inclusion criteria 
 LVEF <45% within 18 months. 
 On stable chronic guideline-directed therapy for HF, including chronic loop diuretics, 
ACEi, ARBs, MRAs, ARNI and β-blockers as tolerated, with no changes to the doses of 
these medications in the past 2 weeks. 
 Taking an oral dose of at least 40 mg furosemide per day or equivalent.  
 Elevated natriuretic peptides (NT-proBNP ≥500 pg/mL or BNP ≥150 pg/mL). For 
patients with atrial fibrillation, NT-proBNP ≥1000 pg/mL or BNP ≥300 pg/mL. 
 eGFR between 30 and 60 mL/min/1.73m2. 
Exclusion criteria 
 SBP <115 mmHg or >180 mmHg at screening or pre-randomisation. 
 Heart rate <50 bpm or >120 bpm at screening or pre-randomisation. 
 Primary HF aetiology attributable to either restrictive/obstructive cardiomyopathy, 
idiopathic hypertrophic or uncorrected severe valvular disease. 
 Hospitalised for acute decompensated HF in the previous month. 
 NYHA Class IV symptoms of HF. 
 Hospitalised with acute coronary syndrome, coronary revascularisation or acute 
myocardial infarction during the previous 90 days prior to screening. 
 History of a CVA, stroke or TIA during the previous 90 days prior to screening. 
 Patients taking thiazides/metolazone or potassium-sparing diuretics (with the 
  
exception of spironolactone or eplerenone at doses ≤50 mg per day, which are 
allowed). 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNi, angiotensin receptor-
neprilysin inhibitor; bpm, beats per minute; BNP, B-type natriuretic peptide; CVA, cerebrovascular accident; eGFR, 
estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, 
mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York 
Heart Association; SBP, systolic blood pressure; TIA, transient ischaemic attack.  
 
 
 
 
 
